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To evaluate the clinical significance of autoantibodies to
three major epithelial cytokeratins (CK)-- CK8, CK18, and
CK19 -- we compared 66 patients with toluene diisocyanate
(TDI)-induced asthma (group I) with three control groups:
169 asymptomatic exposed subjects (group II), 64 patients
with allergic asthma (group III), and 123 unexposed healthy
subjects (group IV). Serum IgG, specific for human recom-
binant CKs, were measured by ELISA (enzyme linked immu-
nosorbent assay), and ELISA inhibition tests were performed.
The existence of these antibodies was confirmed by IgG
immunoblot analysis. Anti-TDI-HSA (human serum albumin)
IgE and IgG antibodies were measured by ELISA in the
same set of the patients. The prevalence of CK8, CK18, and
CK19 auotantibodies in group I was significantly higher than
in the other three groups. Results of the ELISA inhibition test
showed significant inhibition with the addition of three CKs
in a dose-dependent manner. No significant association was
found between CK autoantibodies and the prevalence of anti-
TDI-HSA IgG and IgE antibodies. These results suggest that
autoantibodies to CK18 and CK19 can be used as serologic
markers for identifying patients with TDI-induced asthma
among exposed workers.
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INTRODUCTION
Toluene diisocyanate (TDI) is one of the most
commonly identified causes of occupational
asthma in far-east Asia, with a prevalence of
2.9-13% in exposed workers.
1,2 The pathogenesis
of TDI-induced asthma remains incompletely
understood, and reliable methods of serological
testing have not been established.
Long-term follow-up studies have shown that
more than 50% of patients with TDI-induced
asthma have persistent asthmatic symptoms after
complete avoidance of exposure and after taking
anti-asthmatic medications.
3 Early diagnosis is the
best way to prevent TDI-induced asthma. There
have been several studies finding serologic markers
for early diagnosis. However, the prevalence of
anti-TDI-HSA (human serum albumin) antibodies
was 0-50%, and the sensitivity of anti-TDI-HSA
antibodies was less than fifty.
4 More studies are
needed to determine standardized methods for
detecting specific antibodies. Recent investigations
have demonstrated that inhaled hexamethylene
diisocyanate could conjugate to human airway
epithelial keratins to initiate an immune re-
sponse.
5 Also, our recent study showed that TDI
exposure could increase expression of cytokeratin
(CK) 19 in human bronchial epithelial cells of
patients with TDI-induced asthma.
6 In this study,
we extended these findings and evaluated the
clinical significance of autoantibodies to three
major epithelial CKs -- CK8, 18, and 19 -- in serum
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samples from patients with TDI-induced asthma,
as compared with exposed and unexposed control
subjects.
MATERIALS AND METHODS
Sixty-six patients with TDI-induced asthma,
confirmed by positive responses to TDI broncho-
provocation, were enrolled and classified as group
I. 169 exposed asymptomatic workers (group II),
64 allergic asthma patients that were sensitive to
house dust-mite allergens (group III), and 123
unexposed healthy subjects (group IV) were
enrolled as control subjects. Atopy was deter-
mined by a positive skin test to at least one
common inhalant allergen, including house dust
mites, tree and pollen mixtures, mugwort pollen,
and ragweed pollen, Alternaria (Bencard,
Brentford, U.K.). The demographic data of the
four study groups are compared in Table 1. Serum
samples from group I and III subjects were col-
lected before treatment; all subjects stopped using
inhaled or oral steroids four weeks before the
study. Subjects underwent an interview, chest
radiography, skin-prick test with common inhal-
ant allergens, lung function measurement, and
inhalation challenge with methacholine. All sub-
jects gave informed consent, regulated by the
Institutional Review of Board of Ajou Medical
Center, Suwon, Korea.
Bronchial challenge test with methacholine and
TDI
Subjects in groups I and III underwent metha-
choline bronchial challenge, according to methods
previously described.
4 Briefly, aerosols were
generated by a DeVilbiss 646 nebulizer, connected
to a Devilbiss dosimeter, driven by compressed
air (Devilbis Co., Doylestown, PA, USA). Five
inhalations of normal saline at 5-min intervals
were administered, followed by a series of suc-
cessively doubled doses of methacholine (0.075-25
mg/mL) until a 20% decrease in FEV1 was ob-
served or the maximum dose was given. FEV1 was
measured 5 min after the beginning of each set of
inhalations of aerosolized methacholine. The
methacholine PC20 level was determined by inter-
polation from the dose-response curve. The TDI
bronchial challenge test was performed, according
to a previously described protocol.
4
Preparation of the TDI-HSA conjugate
2,4-TDI-HSA conjugates were prepared, as
described previously, by using a modified version
of Tse and Pesce's method.
4 2,4-TDI (2.4g) was
added to 90 mL of 1% HSA in PBS with constant
stirring. Aliquots were taken 5, 10, 20, 30, and 40
min after the reaction. Ten milliliters of 1% HSA
solution was used as an unconjugated control.
Ammonium carbonate (2 M) was added to each
aliquot to terminate the reactions. All reactive
Table 1. Demographic Data and Levels of CK8, CK18, and CK19 Autoantibodies
Group I (n = 66) Group II (n = 169) Group III (n = 64) Group IV (n = 123)
Age (yrs) 42.8 ± 10.3 41.0 ± 8.4 31.0 ± 11.7 37.2 ± 11.2
Sex (M/F) 46/21 125/44 34/30 70/53
Exposure duration (yrs)* 7.43 ± 4.3 11.53 ± 7.7 NA NA
PC20 Mch (mg/mL) 5.35 ± 8.4 NA 4.41 ± 7.1 NA
IgG to
CK8 116 ± 61.6 52.6 ± 45.1 76.1 ± 35.7 76.3 ± 39.7
CK18 132.1 ± 11.22 62.3 ± 57.3 58.3 ± 68.1 72.7 ± 40.2
CK19 107.7 ± 30.7 55.2 ± 56.0 72.7 ± 40.2 61.6 ± 37.4
Group I, TDI-induced asthma; Group II, asymptomatic exposed controls; Group III, allergic asthma; Group IV, normal controls.
NA not applicaple, All values are presented as mean ± SD; PC20 Mch; methacholine dose at the time of a 20% fall in FEV1 was observed.
*p = 0.01, p < 0.05, significant differences in mean IgG levels between subjects with TDI-induced asthma and the other three groups.Specific IgG to Cytokeratin in TDI-induced Asthma
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samples were centrifuged at 3,000 g for 40 min at
4 to remove unreactive TDI. They were exten-
sively dialyzed for three days against 0.1 mol/L
ammonium carbonate and precipitated with an
equal volume of 20% trichloroacetic acid. Samples
were then redissolved in 1 mol/L sodium hy-
droxide and dialyzed with 4 L of deionized water
for one day. When the degree of substitution was
determined by a modified Gutmann assay, the
molar ratio was 5. The protein content of a con-
jugated sample was determined by the Lowery
method. All reagents used for the preparation of
TDI-HSA conjugates were purchased from Sigma
Chemical Co. (St Louis, MO, USA).
ELISAs to measure anti-TDI-HAS IgG and IgE
antibodies
The serum IgG level was detected by ELISA, as
described previously.
4 In brief, after 1 g of TDI- μ
HSA conjugate or mock conjugate was dissolved
in sodium bicarbonate buffer (pH 9.5), it was
coated onto an ELISA plate individually (Corning,
New York, NY, USA) at 4 . After washing with
PBS-Tween 20 (PBS-T), 350 L of blocking buffer μ
(PBS that contained 1% BSA and 0.1% Tween 20)
was added. Serum from patient or control subjects
was diluted 1 : 5 for IgG and 1 : 3 for IgE in the
preliminary experiments. 50 L of diluted serum μ
was incubated for 1 hr at 37 in both TDI-HSA-
and HSA-coated wells, which were then washed
three times. Peroxidase-conjugated anti-IgG (1 :
2000 v/v, 50 L; Sigma) or biotin-conjugated anti- μ
IgE antibody (1 : 200 v/v, Sigma) was added to
each well, incubated for 1 hr at room temperature,
and washed with PBST. 100 L of streptavidin- μ
peroxidase was added to each IgE-ELISA well for
30 min of incubation at 37 . Then, 100 L of sub μ -
strate solution, dissolved in substrate buffer (3,3',
5,5' tetramethylbenzidine, Sigma), was added.
After 15 min of incubation at 37 , the reactions
were stopped with the addition of 2.5 N H2SO4.
Absorbance values were read, using an ELISA
reader at 405/450 nm. The final absorbance of
each sample was normalized by subtracting the
HSA-coated value from the TDI-HSA-coated
value. The positive cutoff value (0.18 for IgG, and
0.13 for IgE) was determined to be the mean ab-
sorbance of 123 unexposed healthy control sub-
jects plus 2 standard deviations (SD).
IgG autoantibodies to three CKs by ELISA
Serum-specific IgG levels were detected by
ELISA using 50 L of diluted (1 μ : 20) patient serum
or negative control serum. This was determined to
be the optimal concentration in the preliminary
experiment. Prior to the addition of the serum,
each well of the ELISA plates was coated with 100
ng/well of CK8, 18, and 19 (Research Diagnostics,
Flanders, NJ, USA), dissolved in PBS, and was
blocked with 200 L of blocking buffer (PBS that μ
contained 10% FBS). After 1 hour of incubation at
room temperature, the plate was washed three
times with PBS-T. Alkaline phosphatase-conju-
gated anti-human IgG (100 L; Sigma), diluted to μ
1 : 10000 v/v with 10% FBS-PBS, was incubated
for 1 hour at 37 , and was washed with PBS-T.
PNPP (p-nitro-phenyl phosphate; Sigma) was
added as the substrate. Reactions were stopped
with the addition of 1 N NaOH. The optical
density of the solution was determined at 405 nm
by using an ELISA reader. The final absorbance
was determined by subtracting the absorbance of
the uncoated well. Each absorbance was presented
in arbitrary units, based on the standard curve,
which was derived from serial dilutions of the
pooled serum samples with high levels of CK8,
CK18, and CK19 autoantibodies. The positive
cutoff value was determined as the mean absorb-
ance of 123 unexposed healthy control subjects
plus 2 SD.
ELISA inhibition test
Increasing amounts (0.1-100 g/mL) of each CK μ
were dissolved in the blocking solution (PBS that
contained 0.005% Tween 20 and 0.5% nonfat dry
milk) and incubated for 1 hour with pooled serum
samples from patients with TDI-induced asthma,
who had high IgG levels. Then the CK-added
samples were added to the wells of the antigen-
coated microtiter plates, and ELISA experiments
were repeated as described above. The percentage
of inhibition was calculated as follows: % inhi-
bition = 100 × (1-absorbance with inhibitor)/(ab-
sorbance without inhibitor).Young-Min Ye, et al.
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CK immunoblots
Recombinant cytokeratins in 30 mM TRIS hydro-
chloride, 2 mM EDTA, 9.5 M urea, 2 mM DTT, and
10 mM methylammonium chloride (pH 8.0) were
separated by discontinuous SDS-polyacrylamide
gel electrophoresis (PAGE), using a 4-20% Tris-
glycine gradient gel (Invitrogen, Carlsbad, CA,
USA). After electrophoresis, proteins were trans-
ferred onto a polyvinylidene difluoride membrane
(Millipore, Billerica, Mass, USA) and blocked with
5% nonfat milk. After the transfer, membrane
strips were probed with monoclonal antibody to
CK8, CK18, and CK19 (Sigma) at a 1 : 20 dilution
for 3 hours at room temperature. After washing,
each membrane strip was incubated with alkaline
phosphatase-conjugated goat anti-human IgG
(Sigma) for 1 hour at room temperature. The mem-
brane strips were washed again and then stained
with nitroblue tetrazolium/5-bromo-4-chloro-3-
indoyl phosphate (Sigma). The intensity was
measured using a densitometer and presented as
the relative intensity.
Measurement of antinuclear antibody (ANA)
ANA autoantibodies were detected, using Hep
Scan ANA in the serum samples from patients
with TDI-induced asthma and diagnostic kits (BL
Diagnostika, Hamburg, Germany), according to
manufacturer's instructions.
Statistical analysis
The ANOVA test, followed by a post hoc
Scheffe test, was applied to compare demographic
data and the mean level of CK8, CK18, and CK19
autoantibodies among the four study groups. The
Student's t-test was applied to compare PC20
methacholine dose, according to the presence of
specific CK autoantibodies. These continuous
variables did not have a normal distribution and
were log-transformed. They were presented in
their original scale. The cross-tab analysis was
applied to compare the prevalence of specific CK
autoantibodies with specific antibodies to TDI-
HSA conjugate or with laboratory findings. A p-
value of 0.05 or less was regarded as statistically
significant.
RESULTS
CK8, 18, and 19 autoantibodies
Fig. 1 shows the IgG levels for CK8 (Fig. 1A),
CK18 (Fig. 1B), and CK19 (Fig. 1C), obtained by
ELISA, in the four study groups. When the auto-
antibody levels for the three CKs were compared,
there were significant differences among the four
groups. Autoantibody levels to the three CKs
were significantly higher in group I than in the
three control groups (p < 0.05, respectively; Table
1). In group I, CK18 and CK19 (26.2% each) auto
Fig. 1. Detection of CK8 (A), CK18 (B), and CK19 (C) autoantibodies by ELISA in serum samples from the four subject
groups. Group I, patients with TDI-induced asthma; group II, asymptomatic exposed workers; group III, patients with
allergic asthma; and group IV, healthy control subjects. Horizontal bars indicate positive cutoff values. The ANOVA and
post hoc Scheffe test were applied to compare the level of specific IgG to CKs 8, 18, and 19 among the four study groups.
A B CSpecific IgG to Cytokeratin in TDI-induced Asthma
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antibodies were more prevalent than those of CK8
(18.5%). These values were significantly higher than
those of groups II, III, and IV (p< 0.05, Table 2).
Association of anti-TDI-HSA antibodies and
clinical parameters
The prevalence of CK autoantibodies was not
significantly associated with that of anti-TDI-HSA
antibodies and clinical parameters such as sex,
atopy, smoking status, and ANA in patients with
TDI-induced asthma (p > 0.05; Tables 3, 4). In
group I, the PC20 methacholine doses were low in
patients with CK autoantibodies, although the
significances were not documented (for IgG to
CK8 1.97 ± 3.6 vs 5.99 ± 8.9, p = 0.051, for IgG to
Table 2. Prevalence of CK8, CK18, and CK19 Autoantibodies in Serum
Group I (n = 66) Group II (n = 169) Group III (n = 64) Group IV (n = 123) p*
Specific IgG to
CK 8 12 (18.5%)
a 8 (4.7%)
b 2 (3.1%)
b 4 (3.3%)
b < 0.001
CK 18 17 (26.2%)
c 11 (6.5%)
d 3 (4.7%)
d 4 (3.3%)
d < 0.001
CK 19 17 (26.2%)
e 10 (5.9%)
f 2 (3.1%)
f 4 (3.3%)
f < 0.001
Specific IgG to TDI-HSA 11 (16.7%) 9 (5.3%) 0 (0%) 1 (0.8%) < 0.001
Specific IgE to TDI-HSA 5 (7.6%) 1 (0.6%) 0 (0%) 0 (0%) 0.002
*Statistical significance was evaluated by Pearson’s chi-square test between patients in groups I and II.
a-fThe same letters indicate a non-significant difference between groups, based on the Pearson’s chi-square test and Fisher’s exact test.
Table 3. Association of Specific CK Autoantibodies with Clinical Parameters and Anti-TDI-HSA Antibodies in 66 Patients
with TDI-induced Asthma
Parameters
CK 8 CK 18 CK 19
Positive Negative Positive Negative Positive Negative
ANA (n = 53)
Positive 2 3 1 4 1 4
Negative 9 39 15 33 13 35
Smoker (n = 66)
Current 6 17 5 18 6 17
Ex/Non 6 37 12 30 11 32
Sex (n = 66)
Male 2 34 2 34 14 32
Female 1 19 6 14 4 16
Atopy (n = 64)
Present 4 19 5 18 5 18
Absent 7 28 11 24 11 24
IgG to TDI-HSA (n = 66)
Positive 2 9 2 9 1 10
Negative 11 44 16 39 16 39
IgE to TDI-HSA (n = 66)
Positive 2 3 2 3 0 5
Negative 11 50 16 45 17 44
PC20 methacholine dose (mg/mL)
1.97 ± 3.6 5.99 ± 8.9 3.81 ± 7.5 5.93 ± 8.7 3.85 ± 7.5 5.91 ± 8.7Young-Min Ye, et al.
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CK18 3.81 ± 7.5 vs 5.93±8.7, p > 0.05, for IgG to
CK19 3.85 ± 7.5 vs 5.91±8.7, p > 0.05, Table 3).
Among the subjects in group I, a significant
association was noted between the prevalence of
CK19 autoantibodies and the prevalence of CK8
and CK18 autoantibodies (p < 0.001; data not
shown).
ELISA inhibition tests for the three CKs
Fig. 2 shows the results of the ELISA inhibition
test for subjects that tested positive for CK
autoantibodies. Significant, dose-dependent inhi-
bition was noted for each CK.
CK immunoblots
Fig. 3 shows an immunoblot analysis of the
three CKs. Serum samples from patients with
TDI-induced asthma, unexposed healthy control
subjects, and buffer controls were compared with
monoclonal antibodies to the three CKs. Specific
binding to the three CKs was confirmed.
Sensitivity and specificity of CK autoantibodies
in TDI-exposed workers
Table 4 demonstrated the sensitivity, specificity,
test efficiency, and positive and negative predic-
tive values of specific CK autoantibodies and
anti-TDI-HSA antibodies in the study subjects.
The sensitivity and positive predictive value of
CK18 and CK19 autoantibodies were higher than
those of anti-TDI-HSA antibodies. Specificity,
negative predictive value, and test efficiency were
similar in these two groups.
Fig. 2. ELISA inhibition test results for three cytokeratins -- CK8 (A), CK18 (B), and CK19 (C) -- with serial additions of
each cytokeratin ( , CK8; , CK18; , CK 19).
Fig. 3. Immunoblot analysis of recombinant CK8, CK18, and CK19, using serum samples from patients with TDI-induced
asthma (TDI), unexposed healthy control subjects (NC), buffer-only samples or (B) monoclonal antibodies (M) to the three
cytokeratins.
A B CSpecific IgG to Cytokeratin in TDI-induced Asthma
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DISCUSSION
In this study, higher autoantibody levels for the
three epithelial CKs (CK8, CK18, and CK19) were
detected in serum samples from patients with
TDI-induced asthma than in asymptomatic ex-
posed workers, in patients with allergic asthma
and healthy unexposed control subjects. Among
the three autoantibodies, those to CK18 and CK19
showed the highest sensitivities. Furthermore, the
prevalence CK18 and CK19 autoantibodies were
significantly higher in patients with TDI-induced
asthma than in asymptomatic exposed workers,
and their binding specificities were confirmed by
ELISA inhibition tests. Based on the prevalence of
anti-TDI-HSA antibodies observed in this study,
we suggest that serum CK18 and CK19 autoanti-
bodies might be used as serological markers for
identifying patients with TDI-induced asthma
among exposed workers, although the sensitivity
was not high enough (26.2%).
Previous studies on the long-term prognosis of
TDI-induced asthma suggest that early diagnosis
of sensitized patients and immediate removal
from the exposure could increase the likelihood of
remission. However, an appreciable number of
patients with TDI-induced asthma do not recover
completely, even after avoidance and treat-
ment.
3,4,7 Therefore, developing an early diagnos-
tic marker based on serologic tests is essential in
TDI-induced asthma. Although monocyte
chemoattractant protein-1 (MCP-1) could be a
sensitive test to identify diisocyanate (TDI, MDI,
or HDI) induced asthma,
8 this is not easy to repeat
in a larger sample. Several investigators have
detected anti-TDI-HSA IgE and IgG antibodies in
serum samples from patients with TDI- induced
asthma, using ELISA or RAST. The prevalence of
anti-TDI-HSA IgE antibodies has proven quite
variable between laboratories, and sensitivity to
IgG was not high enough.
4,9 This study is the first
to evaluate whether autoantibodies to major
bronchial epithelial CKs can be applied to the
identification of asthma patients exposed to a
single type of isocyanate (patients with TDI-in-
duced asthma vs. TDI-exposed, but asymptomatic
workers), and sensitivity, specificity, positive and
negative predictive value were compared with
those of anti-TDI-HSA IgE and IgG antibodies.
The sensitivities and positive predictive values of
CK18 and CK19 autoantibodies were higher than
those of anti-TDI-HSA IgE and IgG antibodies,
while the specificities, negative predictive values,
and test efficiencies were similar. Significant
associations were not found between the preva-
lence of specific IgE and IgG antibodies. These
findings suggest that autoantibodies to CK18 and
CK19 may be used as a supplementary serologic
markers to increase the diagnostic sensitivities of
serum-specific antibody tests.
Several airway epithelial cell proteins can
conjugate with diisocynates in vitro and in vivo.
6,
10-12 CKs, major intracytoplasmic cytoskeleton
proteins, are potential self-antigens, with a total of
20 human epithelial keratins, based on molecular
weight and isoelectric point. Pairs of CKs seem to
Table 4. Sensitivity and Specificity of CK8, CK18, and CK19 Autoantibodies for Diagnosis of TDI-induced Asthma, Based
on Bronchoprovocation Test Results in 235 TDI Exposed Workers
TP TN FN FP
Sensitivity
(%)
Specificity
(%)
NPV
(%)
PPV
(%)
TE
(%)
IgG to
CK 8 12 161 54 8 18.2 95.2 74.9 60.0 73.6
CK 18 17 158 49 11 26.2 93.5 76.3 60.7 74.5
CK 19 17 159 49 10 26.2 93.5 76.4 62.9 74.9
Specific IgE to TDI-HSA 5 168 61 1 7.6 99.4 73.3 45.4 73.6
Specific IgG to TDI-HSA 11 159 56 9 16.4 94.6 74.0 55.0 72.3
TP, true positive; TN, true negative; FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive
value; TE, test efficiency.Young-Min Ye, et al.
Yonsei Med J Vol. 47, No. 6, 2006
be consistently coexpressed in different types of
epithelial cells.
13 The three CKs applied in this
study have been found in both bronchial and lung
alveolar epithelial cells, which are the major target
tissues of bronchial asthma. The prevalence of
specific CK18 and CK19 autoantibodies were the
same with similar inhibition potencies, according
to the ELISA inhibition test.
CKs are normally located in the intracellular
space and could gain access to the immune
system after epithelial damage or cell death. The
precise mechanism of their generation is still
unknown, although several studies suggest that
CKs are proteolyzed during cell apoptosis and can
leak into the circulation as a soluble form, where
they may serve as new epitopes for antibody
generation.
14-17 In this study, high levels of specific
CK autoantibodies were detected only in patients
with TDI-induced asthma, not in those with al-
lergic asthma. Therefore, these findings may not
be derived from simple epithelial damage found
in asthmatic airways. Among the patients with
TDI-induced asthma, those who are more sus-
ceptible to epithelial damage by TDI exposure
may develop serum-specific CK autoantibodies. In
this study, because we found no association
between these antibodies and the clinical char-
acteristics of TDI-induced asthma, including
asthma symptoms and duration of exposure, we
could not speculate as to which patients would be
susceptible. However, airway hyper-respon-
siveness to methacholine was more severe in
patients with autoantibodies to any of the three
CKs, despite marginal statistical significance.
Further studies are needed to investigate
genetically susceptible markers for developing
autoantibodies to specific CKs among workers
exposed to TDI. How diisocyantes and human
airway epithelial cells are involved in airway
inflammation has not been studied fully.
18 HDI,
conjugated with bronchial CK18, can induce T-cell
proliferation and cytokine production in patients
with diisocyanate asthma.
9,18 Further studies are
needed to confirm whether the development of
autoantibodies to specific CKs is an epiphe-
nomenon of chronic airway damage occurring in
patients with TDI-induced asthma or whether
pathogenic or autoantibody-mediated mechanisms
are involved.
In conclusion, we demonstrated circulating
autoantibodies to three bronchial epithelial CKs
(8, 18, and 19) in patients with TDI-induced
asthma. Among these, autoantibodies to CK18 and
19 may be used as serological markers for the
detection of TDI-induced asthma among workers
with high-risk exposure. Further studies will be
needed to investigate how these specific auto-
antibodies may be involved in the chronic,
persistent airway inflammation found in TDI-
induced asthma.
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